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Objectives: The oxazolidinone linezolid is an effective component of drug-resistant TB treatment, but its use is
limited by toxicity and the optimum dose is uncertain. Current strategies are not informed by clinical pharmaco-
kinetic (PK)/pharmacodynamic (PD) data; we aimed to address this gap.
Methods: We defined linezolid PK/PD targets for efficacy (fAUC0–24:MIC .119 mg/L/h) and safety
(fCmin ,1.38 mg/L). We extracted individual-level linezolid PK data from existing studies on TB patients and per-
formed meta-analysis, producing summary estimates of fAUC0–24 and fCmin for published doses. Combining
these with a published MIC distribution, we performed Monte Carlo simulations of target attainment.
Results: The efficacy target was attained in all simulated individuals at 300 mg q12h and 600 mg q12h, but only
20.7% missed the safety target at 300 mg q12h versus 98.5% at 600 mg q12h. Although suggesting 300 mg
q12h should be used preferentially, these data were reliant on a single centre. Efficacy and safety targets were
missed by 41.0% and 24.2%, respectively, at 300 mg q24h and by 44.6% and 27.5%, respectively, at 600 mg
q24h. However, the confounding effect of between-study heterogeneity on target attainment for q24h regimens
was considerable.
Conclusions: Linezolid dosing at 300 mg q12h may retain the efficacy of the 600 mg q12h licensed dosing with
improved safety. Data to evaluate commonly used 300 mg q24h and 600 mg q24h doses are limited.
Comprehensive, prospectively obtained PK/PD data for linezolid doses in drug-resistant TB treatment are required.
Introduction
TB remains a major global health problem, with 10.4 million
cases and 1.7 million deaths in 2016.1 Although worldwide inci-
dence and mortality have slowly declined over the last 30 years,
the emergence of antibiotic-resistant TB threatens further pro-
gress. MDR-TB, defined as resistance to both rifampicin and isonia-
zid, and rifampicin-resistant (RR) TB (often diagnosed in settings
where genotypic and or/phenotypic drug susceptibility testing to
isoniazid is not available) are more challenging to manage. There
were 600000 estimated cases of RR-TB or MDR-TB worldwide in
2016, with success rates (cure and treatment completion) of
50%.1 Outcomes are particularly poor for MDR-TB patients with
additional resistance to key second-line drugs (any fluoroquino-
lone and at least one second-line injectable agent), classified as
XDR-TB.1–4
Treatment of RR-TB or MDR-TB requires prolonged administra-
tion of multidrug regimens including second-line antibiotics with
reduced efficacy and higher toxicity than first-line drugs.5,6 High
rates of clinical failure, compounded by a rising incidence of
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second-line drug resistance and regular treatment-limiting toxic-
ities, have prompted increased use of the oxazolidinone linezolid
to design adequate regimens. Although currently licensed for use
in Gram-positive bacterial infections, linezolid has bactericidal
activity against Mycobacterium tuberculosis and has been repur-
posed as a class C, core MDR-TB drug.5–8 The standard dose
for treatment of Gram-positive infections in adults is 600 mg twice
daily (q12h) for a maximum of 28 days, but the duration required
for MDR-TB or RR-TB treatment is much longer. Whilst addition
of linezolid to RR-TB or MDR-TB treatment can improve outcomes,
prolonged administration is often limited by toxicity.9–11 Myelosup-
pression (particularly thrombocytopenia) is common. Peripheral
and optic neuropathy, hepatotoxicity, lactic acidosis and hypogly-
caemia are rarer adverse effects, but can be serious (and in the
case of neuropathies, irreversible) when they occur.12,13 Toxicity
from linezolid in TB treatment regularly necessitates dose reduc-
tion, but the optimal safe, efficacious dose remains unknown.
In healthy volunteers, the plasma pharmacokinetics (PK) of
linezolid are 31% protein binding, excellent tissue penetration,
plasma Cmax of 15–27 mg/L, Tmax of 0.5–2 h and a half-life of
3.4–7.4 h.14 However, the PK profile varies between patient
populations; for instance, critically ill patients have increased
levels of free linezolid associated with hypoalbuminaemia,
reduced renal clearance with low body weight and markedly
increased inter-patient variability.15–17 The PK profile of linezolid
in TB patients is poorly characterized and dosing has never been
informed by an analysis of how successfully different doses
might attain target PK/pharmacodynamic (PD) parameters for
efficacy and safety.
We defined PK/PD efficacy and safety targets for linezolid in
clinical TB treatment from the literature and conducted a meta-
analysis of published data collected during therapy to generate
summary estimates of key secondary PK parameters: fAUC0–24
and fCmin. Finally, we simulated attainment of the PK/PD targets
on the basis of the summary estimates obtained and a published
MIC distribution.
Methods
Identifying PK/PD targets
There are no universally accepted PK/PD targets to maximize efficacy and
safety of linezolid in TB therapy. In general, the AUC0–24:MIC ratio is the
PK/PD parameter most predictive of the activity of anti-tuberculous drugs.18
For linezolid, some hollow-fibre infection model (HFIM) and ex vivo
blood culture data suggest that T.MIC may influence efficacy against
M. tuberculosis, but more extensive in vitro, murine and human early bac-
tericidal activity (EBA) studies support AUC0–24:MIC as the main parameter
of interest.19–22 HFIMs corroborate clinical data from Gram-positive infec-
tions, which suggest an efficacy target of fAUC0–24:MIC .100–119 mg/L/h.
We used the more conservative threshold of 119 mg/L/h as the efficacy tar-
get for our simulations.20,23–26
Linezolid clinical toxicity studies are mainly limited to ,28 days. Given
the cumulative nature of linezolid toxicity, these cannot inform PK/PD tar-
gets during prolonged therapy. Amongst the PK parameters, most evidence
exists for a relationship between Cmin and toxicity.
15,27 In the only clinical
study conducted in the context of prolonged TB therapy, all patients with
Cmin .2 mg/L developed an adverse event (principally thrombocytopenia)
versus less than half of those with Cmin ,2 mg/L.
28 We used fCmin
,1.38 mg/L (equivalent to a total Cmin of 2 mg/L) as the safety target for
our simulations.
Systematic review and meta-analysis of linezolid PK
data during TB therapy
To produce summary estimates for fAUC0–24, and fCmin for all dosage regi-
mens currently described, we extracted data from all randomized con-
trolled trials or observational studies published in the English language on
adult (.16 years) TB patients (any resistance pattern) to whom linezolid
was administered for at least 3 days and serum concentrations (at least
Cmax and Cmin or AUC0–24) were assessed using HPLC and reported disaggre-
gated by dose. Single-study data for more than one dosage (mg) in the
same patient was permitted, so long as a minimum washout period of
1 week had taken place. To ensure focus on dosages for which a basic min-
imum of PK evidence was available, we excluded dosages for which ,10
total patients, across studies, were identified.
We searched MEDLINE (1990 to December 2017), EMBASE (1990 to
December 2017), The International Union Against Tuberculosis and Lung
Disease conference abstracts and American Thoracic Society conference
abstracts, using the search terms: Tuberculosis AND (Linezolid OR
Oxazolidinone* OR PNU-100766 OR U-100766). This search was supple-
mented by hand searching the reference lists of identified studies and se-
lected reviews. Authors were contacted to clarify missing or inconsistent
data and, if needed, for individual-level PK data.
We constructed time–concentration curves to calculate fAUC0–24 using
the trapezoid rule.29 fAUC0–24 and fCmin data were normally distributed,
hence the meta-analysis and Monte Carlo simulations used means and
standard deviations as summary descriptors for all studies. If PK results
were not otherwise available, data were extracted from published graphs
using digitizing software (Plot Digitizer, version 2.5.0). Meta-analysis was
conducted using the metafor package in R for Windows, version 3.2.2, to
provide a summary mean fAUC0–24 and fCmin, 95% CI and I
2 statistic for
heterogeneity. To emphasize the importance of the heterogeneity of the
data, we allowed meta-analysis at any level of heterogeneity.
Monte Carlo simulation
Using the summary PK estimates identified, we modelled PK/PD target at-
tainment from 100000 simulated patients at each dose for which data
were available. WT linezolid MIC distributions were derived from previously
published data in drug-susceptible TB. Briefly, this distribution describes the
linezolid MIC results from the isolates of 78 consecutive TB patients in
Sweden who had no resistance to any first-line or major second-line drugs.
The linezolid MICs ranged from 0.125 to 0.5 mg/L (comprising 1 isolate with
an MIC of 0.125 mg/L, 61 isolates with an MIC of 0.25 mg/L and 16 isolates
with an MIC of 0.5 mg/L).30 There are no published linezolid MIC distribu-
tions in RR-TB or MDR-TB. However, MIC values covering 50% and 90% of
isolates (MIC50 and MIC90) in MDR-TB have been reported as 0.25–0.5 and
0.25–1 mg/L, respectively, which is consistent with the WT distribution we
used.31–33 We assumed a log normal distribution for fAUC0–24, fCmin and
fAUC0–24:MIC. We simulated fCmin, fAUC0–24 and MIC for 100000 virtual
patients in R for Windows. The pnormGC function in the tigerstats package
was used to calculate and produce plots of the attainment of the PK/PD tar-
gets. We treated the fAUC0–24 and MIC variables as independent of one an-
other. For doses with high levels of heterogeneity (I2 .50%) we performed
a sensitivity analysis, imputing each study at these doses into the simula-
tion independently to assess the impact of this heterogeneity on target
attainment.
Results
Meta-analysis of existing linezolid PK data in TB therapy
We screened 1602 citations and eight studies were suitable for
meta-analysis. Reasons for inclusion and exclusion are provided in
the PRISMA diagram (Figure 1). Included studies are summarized
and disaggregated by dose in Table 1. We obtained individual
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participant-level data for all of these studies. Data were combined
using a random effects model; forest plots are provided in
Figures 2 and 3. Summary fAUC0–24 and fCmin means and standard
deviations are provided for each dose in Table 1.
At the 300 mg q12h and 600 mg q12h doses, PK sample collec-
tion was intensive across five studies and heterogeneity was lower
(I2 ,50% for fAUC0–24 and fCmin at both doses). However, data at
these doses were reliant on a single centre (three out of five stud-
ies at both doses). Summary estimates for the 300 mg q24h and
600 mg q24h doses relied on sparse sampling from only two stud-
ies and results demonstrated a high degree of inter-study hetero-
geneity (I2"89%–97% for fAUC0–24 and 67%–99% for fCmin).
Monte Carlo simulation of the attainment of
PK/PD targets
Using the summary estimates of fAUC0–24 from the meta-analysis
and the WT MIC distribution we assessed attainment of
fAUC0–24:MIC.119 mg/L/h for each dose in a simulated population
of 100000 individuals (Figure 4).30 The efficacy target was attained
in all simulated individuals at the 300 mg q12h and 600 mg q12h
doses. The target was not attained for 41.0% and 44.6% of simu-
lated individuals at the 300 mg q24h and 600 mg q24h doses, re-
spectively. Given the high heterogeneity between studies at the
300 mg q24h and 600 mg q24h doses, we performed a sensitivity
analysis by imputing each study at these doses into the simulation
independently. In this analysis, the efficacy target was attained by
all individuals in both studies at both doses (Figure 5).
Using the summary estimates for fCmin from the meta-analysis
we simulated the attainment of fCmin ,1.38 mg/L for each dose
(Table 2). More than 98% of individuals at 600 mg q12h and at least
20% of individuals at all doses failed to achieve this target. Again,
because of heterogeneity between studies at the 300 mg q24h and
600 mg q24h doses, we performed a sensitivity analysis, imputing
the individual studies at these doses into the Monte Carlo simula-
tions. Differences between attainment of the safety target when
imputing studies individually were substantial (64.19% for Koh and
Shim34 versus 94.95% for Lee et al.11 at 300 mg q24h and 97.87%
for Dietze et al.21 versus 33.68% for Lee et al.11 at 600 mg q24h).
Discussion
Linezolid is an important drug in the management of RR-TB and
MDR-TB, but its use is often limited by toxicity, prompting consider-
ation of reduced dosing strategies. Our analysis is the first, to our
knowledge, to provide summary PK data and simulate PK/PD tar-
get attainment to inform dose selection in clinical practice and
clinical trials. We meta-analysed published data to generate sum-
mary estimates of plasma fAUC0–24:MIC and fCmin at different
doses of linezolid, then performed Monte Carlo simulations based
on these summary estimates to quantify attainment of putative
PK/PD targets for efficacy and safety.
Current PK data on linezolid in TB patients are limited. Eight clin-
ical studies, using four dosing strategies, were available for our
analysis. These used variable, sometimes sparse, sampling sched-
ules resulting in considerable heterogeneity between studies when
meta-analysing data at 300 mg q24h and 600 mg q24h doses.
Consequently, summary estimates for fAUC0–24 and fCmin at these
doses are accompanied by wide standard deviations. Sensitivity
analyses based on separate simulations for each study at these
doses show that attainment of efficacy and safety targets is
strongly influenced by inter-study heterogeneity. Consequentially,
existing data do not definitively support any one dosing strategy
and further prospective linezolid PK studies, ideally using standar-
dized sampling schedules, are required. Nonetheless, important
observations can be made from our analysis.
MEDLINE
1990 to December 2017
461 Citations
EMBASE
1990 to December 2017
1102 Citations
998 Non-duplicate
citations screened
Review of title and abstract
253 Articles retrieved
745 Articles excluded
1 Article excluded
during data analysis:
data duplicate of
included study
246 Articles excluded
After full text screen:
no linezolid PK data 242
author unable to provide PK data 1
sampling before 3 days of linezolid therapy 1
data not disaggregated by dose 1
errors in linezolid administration 1
Review of full text
8 Articles included
International Union Against Tuberculosis and Lung Disease conference abstracts
2004 to 2017
30 Citations
American Thoracic Society conference abstracts
2009 to 2017
9 Citations
Figure 1. PRISMA flowchart of included and excluded studies for the meta-analysis of existing linezolid PK data in TB therapy.
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Table 1. Meta-analysis of fAUC0–24 (mg/L) and fCmin (mg/L) for different doses of linezolid in TB therapy
Sampling timepoints (h) Number of participants sampled fAUC0–24 mean fAUC0–24 SD fCmin mean fCmin SD
300 mg q24h
Koh and Shim, 200934 0, 2 10 113.56# 49.33# 1.45 0.98
Lee et al., 201211 0, 2 28 64.91* 22.59* 0.87* 0.61*
summary 86.92 149.27 1.09 1.73
300 mg q12h
Bolhuis et al., 201535 0, 1, (2), 3, 4, (5), (8), 12 21 95.45* 41.60* 2.23* 1.47*
Bolhuis et al., 201336 0, 1, 2, 3, 4, 8 5 77.27* 32.05* 1.73* 1.40*
Alffenaar et al., 201037 0, 1, 2, 4, 8, 12 5 80.51* 32.22* 1.37* 0.66*
Alffenaar et al., 201038 0, 1, 2, 4, 8, 12 8 74.53* 26.54* 1.20* 0.85*
Vu et al., 201239 0, 1, 2, 3, 4, 8 2 71.58* 2.49* 0.93* 0.34*
summary 77.82 31.46 1.18 0.94
600 mg q24h
Dietze et al., 200821 0, 1, 2, 4, 8, 12 10 66.10* 18.24* 0.05* 0.14*
Lee et al., 201211 0, 2 38 124.75* 48.74* 1.88* 1.19*
summary 95.18 203.16 0.96 6.34
600 mg q12h
Bolhuis et al., 201535 0, 1, (2), 3, 4, (5), (8), 12 8 134.67 64.17 3.48 2.97
Dietze et al., 200821 0, 1, 2, 4, 8, 12 9 172.75* 61.99* 3.03* 2.00*
Alffenaar et al., 201037 0, 1, 2, 4, 8, 12 4 169.87* 70.53* 3.82* 2.71*
Alffenaar et al., 201038 0, 1, 2, 4, 8, 12 8 180.13* 48.21* 3.48* 1.85*
Vu et al., 201239 0, 1, 2, 3, 4, 8 6 156.31* 59.51* 4.33* 2.50*
summary 165.05 58.5 3.48 2.23
Timepoints in brackets were not sampled for all participants.
Source of data:, from paper; *, from individual-level data provided by authors; #, from graph-digitizing software.
Study
Koh_2009
Lee_2012
Dose
300 mg q24h
300 mg q24h
n
10
28
I2 = 89%
I2 = 44%
I2 = 97%
I2 = 0%
0 50 100 150 200
AUC0-24
Timepoints (h)
0,2
Bolhuis_2013 300 mg q12h 50,1,2,3,4,8
Dietze_2008 600 mg q24h 100,1,2,4,8,12
Lee_2012 600 mg q24h 380,2
Bolhuis_2015 300 mg q12h 210,1,(2),3,4,(5),(8),12
Alffenaar/K_2010 300 mg q12h 50,1,2,4,8,12
Alffenaar/vA_2010 300 mg q12h 80,1,2,4,8,12
Vu_2012 300 mg q12h 20,1,2,3,4,8
Bolhuis_2015 600 mg q12h 80,1,(2),3,4,(5),(8),12
Dietze_2008 600 mg q12h 90,1,2,4,8,12
Alffenaar/K_2010 600 mg q12h 40,1,2,4,8,12
Alffenaar/vA_2010 600 mg q12h 80,1,2,4,8,12
Vu_2012 600 mg q12h 60,1,2,3,4,8
0,2
Figure 2. Forest plot of included studies for meta-analysis of fAUC0–24 at different doses of linezolid. Sampling timepoints in brackets were not as-
sessed for all patients.
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A linezolid dose of 1200 mg/day has recently been used along-
side bedaquiline and pretomanid as part of the Nix-TB trial regimen
(NCT02333799) on the basis of continued dose–response in an
early bactericidal activity study. Preliminary results suggest that
this regimen achieves good clinical outcomes, but 71% of patients
have at least one dose interruption owing to toxicity.40 Prior PK
data are unavailable for 1200 mg q24h, so we meta-analysed
data for 600 mg q12h. In our simulations, 100% attainment of the
efficacy target, but,1% attainment of the safety target, is consist-
ent with the emerging Nix-TB results of high efficacy, but problem-
atic, side effects. The ZeNix trial (NCT03086486) will test the
efficacy and toxicity of 600 mg q24h versus 1200 mg q24h of line-
zolid within this regimen.
In search of a less toxic dosing regimen, prior meta-analyses
support the clinical efficacy of linezolid 600 mg/day or lower.9,10
One lower-dose linezolid strategy is 300 mg q12h, for which our
simulations described 100% efficacy target attainment and failure
to meet the safety target in only 20.7% of patients. These results
support preferential use of this dose. However, as many patients
were from a single centre, generalizability of this finding will de-
pend on prospective studies in other populations. Alternatively,
once-daily dosing at 600 mg q24h is often advocated because of
Study
Koh_2009
Lee_2012
Dose
300 mg q24h
300 mg q24h
n
10
28
I2 = 67%
I2 = 0%
I2 = 99%
I2 = 0%
0 1 2 3 4 5 6 7 8
Cmin
Timepoints (h)
0,2
Bolhuis_2013 300 mg q12h 50,1,2,3,4,8
Dietze_2008 600 mg q24h 100,1,2,4,8,12
Lee_2012 600 mg q24h 380,2
Bolhuis_2015 300 mg q12h 210,1,(2),3,4,(5),(8),12
Alffenaar/K_2010 300 mg q12h 50,1,2,4,8,12
Alffenaar/vA_2010 300 mg q12h 80,1,2,4,8,12
Vu_2012 300 mg q12h 20,1,2,3,4,8
Bolhuis_2015 600 mg q12h 80,1,(2),3,4,(5),(8),12
Dietze_2008 600 mg q12h 90,1,2,4,8,12
Alffenaar/K_2010 600 mg q12h 40,1,2,4,8,12
Alffenaar/vA_2010 600 mg q12h 80,1,2,4,8,12
Vu_2012 600 mg q12h 60,1,2,3,4,8
0,2
Figure 3. Forest plot of included studies for meta-analysis of fCmin at different doses of linezolid. Sampling timepoints in brackets were not assessed
for all patients.
AUC/MIC = 119
0.008
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AUC/MIC
800
300 mg q24h, P(AUC/MIC) <199 = 41%
300 mg q12h, P(AUC/MIC) <119 = 0%
600 mg q24h, P(AUC/MIC) <119 = 45%
600 mg q12h, P(AUC/MIC) <119 = 0%
1000
Figure 4. Probability density distributions of the attainment of linezolid fAUC0–24:MIC .119 mg/L/h (vertical line) in a Monte Carlo simulation of
100000 patients at different doses of linezolid, based on a published MIC distribution and summary AUC0–24 from a meta-analysis of published data.
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greater convenience. Our simulations were based on a meta-
analysis of two studies and described only 55.5% efficacy target
attainment and failure to meet the safety target in 27.5% of simu-
lated patients. Assuming a half-life of 5 h, accumulation ratios of
1.03 and 1.23 are expected for q24h and q12h linezolid dosing
regimens, respectively, so the AUC0–24 for linezolid may be up to
20% higher for 300 mg q12h than 600 mg q24h and this may have
contributed to higher efficacy target attainment with the 300 mg
q12h dose. However, as our sensitivity analyses show that hetero-
geneity of study results strongly influenced attainment of efficacy
and safety targets in simulations at 600 mg q24h, further studies
are required before judgement can be passed on this dosing
strategy.
A lower linezolid dose of 300 mg q24h is used clinically, particu-
larly in patients who have already reported side effects. We found
limited PK assessment of this strategy. In simulations based on
meta-analysis of data from two studies, efficacy target attain-
ment and failure to meet the safety target were similar to 600 mg
q24h at 59.0% and 24.5%, respectively. This demonstrates that ef-
fective therapy is possible at 300 mg q24h for some individuals,
but that linezolid will cause some toxicity irrespective of dose alter-
ation. As with 600 mg q24h, the high degree of heterogeneity in
study results at this dose complicates these analyses and under-
lines the need for prospectively gathered PK data at this clinically
important dose.
Overall, these data suggest that future clinical trials containing
linezolid should evaluate multiple dosing regimens and that
trials of alternative oxazolidinones that retain efficacy with lower
toxicity are urgently needed. For instance, sutezolid has demon-
strated greater antimycobacterial activity than linezolid in a
whole-blood culture model, treatment shortening in a mouse
model and sustained EBA0–14 in humans (which have not been
demonstrated with linezolid), whilst demonstrating a more fa-
vourable PK/PD profile in terms of likely mitochondrial inhibition
and apparently lower rates of toxicity in small, limited-duration,
human studies.8,41,42 Trials of cyclical linezolid courses to maxi-
mize efficacy and then allow cumulative toxicity to abate should
be considered; we could not assess this strategy in our analysis.
Intermittent dosing strategies have been proposed, whereby a
higher linezolid dose (e.g. 1200 mg) is given on alternate days to
ensure efficacy target attainment, but allow longer periods of
safety target attainment.43 Our data provide supportive evidence
that the summary estimate of AUC0–24 for 600 mg q12h approxi-
mates a doubling of the 300 mg q12h and 600 mg q24h summary
estimates for AUC0–24, but existing data do not allow us to
comment on any improvements in safety target attainment with
intermittent dosing. Whilst revised dosing strategies are being es-
tablished, therapeutic drug monitoring may have a role in maxi-
mizing attainment of efficacy and safety targets for individual
patients. Moreover, population PK models indicate that renal clear-
ance accounts for up to 70% of inter-individual variation in linezolid
levels, suggesting a potential benefit from initial dosing based on
renal function, formulae for which have been proposed.13,44
In addition to highlighting the need for more PK data, this study
has several limitations. Our putative PK/PD efficacy and safety tar-
gets may not be precise. The efficacy target was based on HFIM
data in the absence of any measurement validated against clinical
outcomes. The safety target was derived from one clinical study
from Asia, with thrombocytopenia as the principal outcome.28 This
may not be representative of overall linezolid toxicity. More robust
linezolid PK/PD targets for TB therapy require prospective clinical
evaluation. Secondly, the WT linezolid MIC distribution used for
fAUC:MIC simulations was from drug-susceptible TB because there
are no published linezolid MIC distributions for RR-TB or MDR-TB.
However, MIC50 and MIC90 values for these populations are in
broad agreement with the WT data.31–33 Additionally, the MIC
testing for this distribution was conducted using Middlebrook 7H10
media and may not be representative of the distribution obtained
using alternative media.30 Thirdly, development of linezolid
0 200
AUC/MIC = 119
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Koh et al. 300 mg q24h P(AUC/MIC) <119 = 0%
Lee et al. 300 mg q24h P(AUC/MIC) <119 = 0%
Dietze et al. 600 mg q24h P(AUC/MIC) <119 = 0%
Lee et al. 600 mg q24h P(AUC/MIC) <119 = 0%
AUC/MIC
600 800 1000
Figure 5. Probability density distributions of the attainment of linezolid fAUC0–24:MIC .119 mg/L/h (vertical line) in a Monte Carlo simulation of
100000 patients at different doses of linezolid, based on a published MIC distribution and summary AUC0–24 in a sensitivity analysis imputing individ-
ual studies at the 300 mg q24h and 600 mg q24h doses separately.
Table 2. Percentage of 100000 simulated patients below a safety
threshold, fCmin ,1.38 mg/L, based on summary PK data for different
linezolid doses
Dose Percentage below 1.38 mg/L
300 mg q24h 75.47%
300 mg q12h 79.30%
600 mg q24h 72.53%
600 mg q12h 1.42%
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resistance during therapy is an important outcome and may be a
particular risk at lower doses.45 We have not yet simulated the at-
tainment of resistance prevention PK/PD targets and future studies
should seek to do this.
In conclusion, despite increased use of linezolid in RR-TB and
MDR-TB treatment, there remains no consensus on optimal safe
dosing. Current PK/PD data are insufficient to confidently provide a
solution. Compared with the standard dose of 600 mg q12h, a
dose of 300 mg q12h may retain efficacy with lower toxicity.
Prospective clinical studies are required to test this proposition and
to better assess once-daily dosing strategies.
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